These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1369 related items for PubMed ID: 16490472

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus.
    Sowers JR, White WB, Pitt B, Whelton A, Simon LS, Winer N, Kivitz A, van Ingen H, Brabant T, Fort JG, Celecoxib Rofecoxib Efficacy and Safety in Comorbidities Evaluation Trial (CRESCENT) Investigators.
    Arch Intern Med; 2005 Jan 24; 165(2):161-8. PubMed ID: 15668361
    [Abstract] [Full Text] [Related]

  • 4. Celecoxib plus aspirin versus naproxen and lansoprazole plus aspirin: a randomized, double-blind, endoscopic trial.
    Goldstein JL, Cryer B, Amer F, Hunt B.
    Clin Gastroenterol Hepatol; 2007 Oct 24; 5(10):1167-74. PubMed ID: 17916545
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Valdecoxib is associated with improved dyspepsia-related health compared with nonspecific NSAIDs in patients with osteoarthritis or rheumatoid arthritis.
    Rabeneck L, Goldstein JL, Vu A, Mayne TJ, Rublee DA.
    Am J Gastroenterol; 2005 May 24; 100(5):1043-50. PubMed ID: 15842577
    [Abstract] [Full Text] [Related]

  • 7. Celecoxib in the treatment of primary dysmenorrhea: results from two randomized, double-blind, active- and placebo-controlled, crossover studies.
    Daniels S, Robbins J, West CR, Nemeth MA.
    Clin Ther; 2009 Jun 24; 31(6):1192-208. PubMed ID: 19695387
    [Abstract] [Full Text] [Related]

  • 8. Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo.
    Bensen WG, Zhao SZ, Burke TA, Zabinski RA, Makuch RW, Maurath CJ, Agrawal NM, Geis GS.
    J Rheumatol; 2000 Aug 24; 27(8):1876-83. PubMed ID: 10955327
    [Abstract] [Full Text] [Related]

  • 9. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor.
    Goldstein JL, Silverstein FE, Agrawal NM, Hubbard RC, Kaiser J, Maurath CJ, Verburg KM, Geis GS.
    Am J Gastroenterol; 2000 Jul 24; 95(7):1681-90. PubMed ID: 10925968
    [Abstract] [Full Text] [Related]

  • 10. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis.
    Goldstein JL, Correa P, Zhao WW, Burr AM, Hubbard RC, Verburg KM, Geis GS.
    Am J Gastroenterol; 2001 Apr 24; 96(4):1019-27. PubMed ID: 11316141
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis.
    Schneeweiss S, Solomon DH, Wang PS, Rassen J, Brookhart MA.
    Arthritis Rheum; 2006 Nov 24; 54(11):3390-8. PubMed ID: 17075817
    [Abstract] [Full Text] [Related]

  • 14. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis.
    Maetzel A, Krahn M, Naglie G.
    Arthritis Rheum; 2003 Jun 15; 49(3):283-92. PubMed ID: 12794781
    [Abstract] [Full Text] [Related]

  • 15. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial.
    Bensen WG, Fiechtner JJ, McMillen JI, Zhao WW, Yu SS, Woods EM, Hubbard RC, Isakson PC, Verburg KM, Geis GS.
    Mayo Clin Proc; 1999 Nov 15; 74(11):1095-105. PubMed ID: 10560596
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A randomized, multicentre, double-blind, parallel-group study to assess the adverse event-related discontinuation rate with celecoxib and diclofenac in elderly patients with osteoarthritis.
    Dahlberg LE, Holme I, Høye K, Ringertz B.
    Scand J Rheumatol; 2009 Nov 15; 38(2):133-43. PubMed ID: 19165648
    [Abstract] [Full Text] [Related]

  • 18. The hepatic safety and tolerability of the cyclooxygenase-2 selective NSAID celecoxib: pooled analysis of 41 randomized controlled trials.
    Soni P, Shell B, Cawkwell G, Li C, Ma H.
    Curr Med Res Opin; 2009 Aug 15; 25(8):1841-51. PubMed ID: 19530981
    [Abstract] [Full Text] [Related]

  • 19. Gastrointestinal tolerability of NSAIDs in elderly patients: a pooled analysis of 21 randomized clinical trials with celecoxib and nonselective NSAIDs.
    Mallen SR, Essex MN, Zhang R.
    Curr Med Res Opin; 2011 Jul 15; 27(7):1359-66. PubMed ID: 21561397
    [Abstract] [Full Text] [Related]

  • 20. Cardiovascular events associated with the use of four nonselective NSAIDs (etodolac, nabumetone, ibuprofen, or naproxen) versus a cyclooxygenase-2 inhibitor (celecoxib): a population-based analysis in Taiwanese adults.
    Huang WF, Hsiao FY, Wen YW, Tsai YW.
    Clin Ther; 2006 Nov 15; 28(11):1827-36. PubMed ID: 17213003
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 69.